Aromatase inhibitor: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz No edit summary |
mNo edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 7: | Line 7: | ||
==References== | ==References== | ||
{{reflist}}[[Category:Suggestion Bot Tag]] | |||
Latest revision as of 06:00, 13 July 2024
Aromatase inhibitors, which inhibit the enzyme aromatase used biologically to produce estrogens, inhibit the biosynthetic production of estrogen steroids. Because of this action, these inhibitors are sometimes used to treat cancerous tumors, which are estrogen-sensitive, especially breast cancer in postmenopausal women. At present, three AIs are approved by the FDA[1] :
- anastrazole (Arimidex®)
- exemestane (Aromasin®)
- letrozole (Femara®)